Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

301.19 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation

April 20, 2026

Via Investor Brand Network

Topics Artificial Intelligence

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

Via Investor Brand Network

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

March 30, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

From BioMedWire

Via GlobeNewswire

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

March 24, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast TTR Investor Webinar

March 10, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

February 23, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

February 19, 2026

Via Investor Brand Network

Topics Intellectual Property

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

February 19, 2026

From BioMedWire

Via GlobeNewswire

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

February 12, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

January 29, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

January 11, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

December 17, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

December 11, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Announces Changes to Board of Directors

December 03, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

November 08, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

November 04, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

October 30, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

October 16, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

October 01, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

September 29, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

September 09, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

September 08, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM

August 31, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

August 30, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

August 27, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

August 11, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

August 05, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

July 31, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.